These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10971448)

  • 21. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
    Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
    Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly.
    Parkinson C; Renehan AG; Ryder WD; O'Dwyer ST; Shalet SM; Trainer PJ
    Clin Endocrinol (Oxf); 2002 Jul; 57(1):59-64. PubMed ID: 12100070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inverse correlation between insulin-like growth factor binding protein-1 and insulin in patients with acromegaly during treatment with the somatostatin analogue octreotide.
    Fredstorp L; Werner S; Bang P; Hall K
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):495-501. PubMed ID: 7525123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum IGF-I and IGFBP-3 levels for the assessment of disease activity of acromegaly.
    Chen HS; Lin HD
    J Endocrinol Invest; 1999 Feb; 22(2):98-103. PubMed ID: 10195375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circadian variation in serum free and total insulin-like growth factor (IGF)-I and IGF-II in untreated and treated acromegaly and growth hormone deficiency.
    Skjaerbaek C; Frystyk J; Kaal A; Laursen T; Møller J; Weeke J; Jørgensen JO; Sandahl Christiansen J; Orskov H
    Clin Endocrinol (Oxf); 2000 Jan; 52(1):25-33. PubMed ID: 10651750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly.
    Grinspoon S; Clemmons D; Swearingen B; Klibanski A
    J Clin Endocrinol Metab; 1995 Mar; 80(3):927-32. PubMed ID: 7533774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly.
    Colao A; Spiezia S; Cerbone G; Pivonello R; Marzullo P; Ferone D; Di Somma C; Assanti AP; Lombardi G
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):515-24. PubMed ID: 11318788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin?
    Riedel M; Günther T; von zur Mühlen A; Brabant G
    Clin Endocrinol (Oxf); 1992 Sep; 37(3):233-9. PubMed ID: 1358484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.
    Arosio M; Garrone S; Bruzzi P; Faglia G; Minuto F; Barreca A
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1091-8. PubMed ID: 11238491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of different methods for diagnosing acromegaly.
    Stoffel-Wagner B; Springer W; Bidlingmaier F; Klingmüller D
    Clin Endocrinol (Oxf); 1997 May; 46(5):531-7. PubMed ID: 9231047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating adiponectin levels and cardiovascular risk factors in acromegalic patients.
    Ronchi CL; Corbetta S; Cappiello V; Morpurgo PS; Giavoli C; Beck-Peccoz P; Arosio M; Spada A
    Eur J Endocrinol; 2004 May; 150(5):663-9. PubMed ID: 15132722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The relationship between serum levels of insulin-like growth factor-I and its binding proteins and microvascular function in acromegalic patients.
    Krsek M; Prázný M; Marek J; Skrha J; Justová V; Lacinová Z
    Growth Horm IGF Res; 2002 Feb; 12(1):54-9. PubMed ID: 12127302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum lipoproteins in acromegaly before and 6-15 months after transsphenoidal adenomectomy.
    Oscarsson J; Wiklund O; Jakobsson KE; Petruson B; Bengtsson BA
    Clin Endocrinol (Oxf); 1994 Nov; 41(5):603-8. PubMed ID: 7828349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
    Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F
    J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum ghrelin levels and disturbances of the lipid profile in patients with acromegaly.
    Jaskula M; Wasko R; Komarowska H; Dziubandowska A; Sowinski J
    Neuro Endocrinol Lett; 2009; 30(2):245-55. PubMed ID: 19675514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1.
    Parfitt VJ; Flanagan D; Wood P; Leatherdale BA
    Clin Endocrinol (Oxf); 1998 Nov; 49(5):647-52. PubMed ID: 10197081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low dose continuously infused growth hormone results in increased lipoprotein(a) and decreased low density lipoprotein cholesterol concentrations in middle-aged men.
    Oscarsson J; Ottosson M; Wiklund O; Mårin P; Vikman-Adolfsson K; Björntorp P; Edén S
    Clin Endocrinol (Oxf); 1994 Jul; 41(1):109-16. PubMed ID: 8050123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly.
    Ezzat S; Ren SG; Braunstein GD; Melmed S
    J Clin Endocrinol Metab; 1991 Aug; 73(2):441-3. PubMed ID: 1713220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion.
    Bates AS; Evans AJ; Jones P; Clayton RN
    Clin Endocrinol (Oxf); 1995 Apr; 42(4):417-23. PubMed ID: 7750196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth hormone, IGF-I and its binding proteins (IGFBP-1 and -3) in adult uraemic patients undergoing peritoneal dialysis and haemodialysis.
    Iglesias P; Díez JJ; Fernández-Reyes MJ; Méndez J; Bajo MA; Aguilera A; Selgas R
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):741-9. PubMed ID: 15163339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.